Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
ENZN's Cash to Debt is ranked higher than
89% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. ENZN: No Debt )
ENZN' s 10-Year Cash to Debt Range
Min: 0.23   Max: No Debt
Current: No Debt

Equity to Asset 0.74
ENZN's Equity to Asset is ranked higher than
78% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ENZN: 0.74 )
ENZN' s 10-Year Equity to Asset Range
Min: -0.14   Max: 0.93
Current: 0.74

-0.14
0.93
Interest Coverage 8.55
ENZN's Interest Coverage is ranked higher than
51% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ENZN: 8.55 )
ENZN' s 10-Year Interest Coverage Range
Min: 0.24   Max: 9999.99
Current: 8.55

0.24
9999.99
F-Score: 6
Z-Score: -0.33
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 52.65
ENZN's Operating margin (%) is ranked higher than
99% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. ENZN: 52.65 )
ENZN' s 10-Year Operating margin (%) Range
Min: -113.51   Max: 52.65
Current: 52.65

-113.51
52.65
Net-margin (%) 52.62
ENZN's Net-margin (%) is ranked higher than
98% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. ENZN: 52.62 )
ENZN' s 10-Year Net-margin (%) Range
Min: -111.49   Max: 181.11
Current: 52.62

-111.49
181.11
ROE (%) 345.39
ENZN's ROE (%) is ranked higher than
100% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. ENZN: 345.39 )
ENZN' s 10-Year ROE (%) Range
Min: -155.66   Max: 345.39
Current: 345.39

-155.66
345.39
ROA (%) 254.88
ENZN's ROA (%) is ranked higher than
100% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. ENZN: 254.88 )
ENZN' s 10-Year ROA (%) Range
Min: -80.49   Max: 254.88
Current: 254.88

-80.49
254.88
Revenue Growth (%) -25.90
ENZN's Revenue Growth (%) is ranked higher than
63% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. ENZN: -25.90 )
ENZN' s 10-Year Revenue Growth (%) Range
Min: -40.6   Max: 95.5
Current: -25.9

-40.6
95.5
EBITDA Growth (%) 38.70
ENZN's EBITDA Growth (%) is ranked higher than
97% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. ENZN: 38.70 )
ENZN' s 10-Year EBITDA Growth (%) Range
Min: -55.1   Max: 66.5
Current: 38.7

-55.1
66.5
» ENZN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ENZN Guru Trades in Q1 2013

Charles Brandes 360,865 sh (+432.17%)
Carl Icahn 5,904,863 sh (unchged)
Michael Price 748,800 sh (unchged)
First Pacific Advisors 379,826 sh (unchged)
Carl Icahn Sold Out
Seth Klarman 7,691,453 sh (-2.02%)
Jim Simons 886,184 sh (-9.66%)
» More
Q2 2013

ENZN Guru Trades in Q2 2013

Charles Brandes 1,026,723 sh (+184.52%)
Jim Simons 910,308 sh (+2.72%)
Seth Klarman 7,691,453 sh (unchged)
Carl Icahn 5,904,863 sh (unchged)
First Pacific Advisors 379,826 sh (unchged)
Michael Price 748,200 sh (-0.08%)
» More
Q3 2013

ENZN Guru Trades in Q3 2013

Charles Brandes 1,027,743 sh (+0.1%)
Carl Icahn 5,904,863 sh (unchged)
Seth Klarman 7,691,453 sh (unchged)
Michael Price 748,200 sh (unchged)
First Pacific Advisors 377,035 sh (-0.73%)
Jim Simons 819,984 sh (-9.92%)
» More
Q4 2013

ENZN Guru Trades in Q4 2013

Paul Tudor Jones 36,398 sh (New)
Michael Price 748,200 sh (unchged)
Carl Icahn 5,904,863 sh (unchged)
Charles Brandes 1,023,893 sh (-0.37%)
Jim Simons 765,284 sh (-6.67%)
First Pacific Advisors 347,035 sh (-7.96%)
Seth Klarman 4,337,858 sh (-43.6%)
» More
» Details

Insider Trades

Latest Guru Trades with ENZN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Seth Klarman 2013-12-31 Reduce -43.6%0.16%$1.15 - $1.74 $ 0.98-36%4337858
Charles Brandes 2013-06-30 Add 184.52%0.02%$1.6 - $3.95 $ 0.98-67%1026723
Charles Brandes 2013-03-31 Add 432.17%0.01%$3.79 - $4.99 $ 0.98-78%360865
Jean-Marie Eveillard 2012-12-31 Sold Out 0.01%$4.35 - $7 $ 0.98-84%0
Charles Brandes 2012-12-31 Add 35.19%$4.35 - $7 $ 0.98-84%67810
Jean-Marie Eveillard 2012-09-30 Reduce -56.42%0.02%$6.42 - $7.17 $ 0.98-86%490142
Charles Brandes 2012-06-30 Add 58.41%$5.87 - $7.06 $ 0.98-85%51070
Charles Brandes 2012-03-31 New Buy$6.54 - $7.82 $ 0.98-85%32240
Richard Perry 2011-09-30 Sold Out 0.5937%$7.24 - $10.37 $ 0.98-89%0
Carl Icahn 2011-09-30 Add 25%0.07%$7.24 - $10.37 $ 0.98-89%5904863
Richard Perry 2011-06-30 Reduce -30.35%0.31%$9.97 - $11.81 $ 0.98-91%2013000
George Soros 2011-06-30 Sold Out $9.97 - $11.81 $ 0.98-91%0
Michael Price 2011-03-31 Add 16.65%0.16%$10.14 - $12.48 $ 0.98-91%700000
George Soros 2011-03-31 Reduce -52.5%$10.14 - $12.48 $ 0.98-91%30400
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Enzon Pharmaceuticals, Inc.

GuruFocus Real Time Picks of the Week
The following information is a highlight of the real-time guru activity we saw this week. To view more information on these gurus, check out their guru portfolios. The “Real Time Picks” reports the stock purchases and sells that Gurus have made within the prior two weeks. If a Guru makes a purchase or sell of a company in which they own a greater-than 5% stake, SEC regulations require them to report their transaction within two days. This week we saw notable increases in Real Time activity from Seth Klarman (Trades, Portfolio), Jean-Marie Eveillard (Trades, Portfolio) and Chris Davis (Trades, Read more...
Seth Klarman Buys New Stock Kindred Biosciences, Cuts Stake in Enzon
Seth Klarman (Trades, Portfolio) of the Boston-based Baupost Group, which trades sparingly, has purchased a new stock: Kindred Biosciences (KIN), according to GuruFocus Real Time Picks. Read more...
Charles Brandes Top Second Quarter Portfolio Changes
A disciple of value investing Guru Benjamin Graham, Charles Brandes founded Brandes Investment Partners in 1974. Brandes' funds continue to perform well, with both the Global Equity fund and the International Equity fund producing double-digit returns over the past year. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 2.20
ENZN's P/E(ttm) is ranked higher than
98% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 28.60 vs. ENZN: 2.20 )
ENZN' s 10-Year P/E(ttm) Range
Min: 2.05   Max: 1354.17
Current: 2.2

2.05
1354.17
P/B 8.30
ENZN's P/B is ranked lower than
54% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. ENZN: 8.30 )
ENZN' s 10-Year P/B Range
Min: 0.95   Max: 13.17
Current: 8.3

0.95
13.17
P/S 1.44
ENZN's P/S is ranked higher than
96% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. ENZN: 1.44 )
ENZN' s 10-Year P/S Range
Min: 0.96   Max: 11.93
Current: 1.44

0.96
11.93
PFCF 3.00
ENZN's PFCF is ranked higher than
99% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 30.00 vs. ENZN: 3.00 )
ENZN' s 10-Year PFCF Range
Min: 2.61   Max: 428
Current: 3

2.61
428
EV-to-EBIT 1.90
ENZN's EV-to-EBIT is ranked higher than
91% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. ENZN: 1.90 )
ENZN' s 10-Year EV-to-EBIT Range
Min: 1.6   Max: 976.9
Current: 1.9

1.6
976.9
Shiller P/E 2.20
ENZN's Shiller P/E is ranked higher than
98% of the 175 Companies
in the Global Biotechnology industry.

( Industry Median: 38.74 vs. ENZN: 2.20 )
ENZN' s 10-Year Shiller P/E Range
Min: 1.98   Max: 151.6
Current: 2.2

1.98
151.6

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.90
ENZN's Price/Net Cash is ranked higher than
57% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. ENZN: 8.90 )
ENZN' s 10-Year Price/Net Cash Range
Min: 2.61   Max: 90.58
Current: 8.9

2.61
90.58
Price/Net Current Asset Value 8.90
ENZN's Price/Net Current Asset Value is ranked higher than
57% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. ENZN: 8.90 )
ENZN' s 10-Year Price/Net Current Asset Value Range
Min: 2.61   Max: 106.25
Current: 8.9

2.61
106.25
Price/Tangible Book 8.20
ENZN's Price/Tangible Book is ranked lower than
51% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. ENZN: 8.20 )
ENZN' s 10-Year Price/Tangible Book Range
Min: 1.64   Max: 131.63
Current: 8.2

1.64
131.63
Price/DCF (Projected) 0.40
ENZN's Price/DCF (Projected) is ranked higher than
99% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 2.80 vs. ENZN: 0.40 )
ENZN' s 10-Year Price/DCF (Projected) Range
Min: 0.44   Max: 35.71
Current: 0.4

0.44
35.71
Price/Median PS Value 0.50
ENZN's Price/Median PS Value is ranked higher than
93% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ENZN: 0.50 )
ENZN' s 10-Year Price/Median PS Value Range
Min: 0.45   Max: 32.95
Current: 0.5

0.45
32.95
Price/Graham Number 0.90
ENZN's Price/Graham Number is ranked higher than
93% of the 243 Companies
in the Global Biotechnology industry.

( Industry Median: 3.00 vs. ENZN: 0.90 )
ENZN' s 10-Year Price/Graham Number Range
Min: 0.62   Max: 65.81
Current: 0.9

0.62
65.81
Earnings Yield (Greenblatt) 53.40
ENZN's Earnings Yield (Greenblatt) is ranked higher than
88% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. ENZN: 53.40 )
ENZN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 62.7
Current: 53.4

0.1
62.7
Forward Rate of Return (Yacktman) 42.06
ENZN's Forward Rate of Return (Yacktman) is ranked higher than
98% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. ENZN: 42.06 )
ENZN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.8   Max: 54.6
Current: 42.06

-0.8
54.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:EZ1.Germany
Enzon Pharmaceuticals, Inc., a biotechnology company, was founded on 1981. The Company is engaged in the research and development of therapeutics for cancer patients primarily in the United States. Its drug development programs utilize two platforms - Customized PEGylation Linker Technology and third-generation messenger ribonucleic acid antagonists utilizing the Locked Nucleic Acid technology. Its development pipeline comprises various novel compounds, including PEG-SN38, which is in Phase II clinical trials for the treatment of metastatic colorectal and breast cancer; and Phase I trial for pediatric patients with cancer. Its development pipeline also includes mRNA antagonists, such as hypoxia-inducible factor-1 alpha that is in Phase I study in patients with solid tumors and lymphoma to evaluate various dosing schedules; Survivin, which is in Phase I study in patients with solid tumors and lymphoma; and androgen receptor, a novel antagonist that is in Phase I study in patients with castration-resistant prostate cancer. In addition, the company has LNA targets in various stages of preclinical research. It has collaboration agreement with National Cancer Institute for conducting a pilot study in patients with tumors in the liver; and has a license and collaboration agreement with Santaris Pharma A/S for mRNA antagonists. The Company has a strategic alliance with Zhejiang Hisun Pharmaceuticals Co. Ltd for the research and development of therapeutics using the company's customized PEGylation linker technology.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide